Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach.
In this study the effect of purified rat anti-mouse IL-5 monoclonal antibody on aeroallergen-induced infiltration of eosinophils in the bronchoalveolar lavage fluid of guinea pigs was studied. The i.p. injection of anti-IL-5 antibody 4 h after aeroallergen challenge inhibited eosinophil infiltration in a dose-dependent fashion. The resulting ED50 was 10 (3.4-32.8) micrograms/kg. The clinical therapeutic usefulness of anti-IL-5 or anti-IL-5-producing cells in asthma/allergy treatment remains to be an intriguing possibility.
Chand
N
N
Wallace Laboratories, Division of Carter-Wallace, Inc., Cranbury, NJ 08512.
Harrison
J E
JE
Rooney
S
S
Pillar
J
J
Jakubicki
R
R
Nolan
K
K
Diamantis
W
W
Sofia
R D
RD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D004802:Eosinophilia / Q000276:immunology / Q000628:therapy*; D006168:Guinea Pigs; D015848:Interleukin-5 / Q000276:immunology*; D008297:Male
D000911:Antibodies, Monoclonal; D015848:Interleukin-5